Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
ADAPT-E
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
- NCT04585477 ↗
- Suspended
- Stanford University
- Focused
We haven't built an HCP commentary report on ADAPT-E (durvalumab in Non-small Cell Lung Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ADAPT-E so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 5 |
The trial
ClinicalTrials.gov- Official title
- Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
- Phase
- Phase 2
- Status
- Suspended
- Conditions
- Non-small Cell Lung Cancer; Non-small Cell Lung Cancer Stage I; Non-small Cell Lung Cancer Stage II; Non-small Cell Lung Cancer Stage III
- Interventions
- AVENIO ctDNA Surveillance Kit; Durvalumab; Durvalumab (Imfinzi) alone or in combination with platinum-based chemotherapy
- Arms
- Cohort 1 minimal residue disease positive(MRD+) · Experimental
- Cohort 2 minimal residue disease negative (MRD-) · Active comparator
- Enrollment
- 80 (estimated)
- Primary outcomes
- Decrease in ctDNA Level
- Sponsor
- Stanford University with AstraZeneca
- Start
- Apr 8, 2021
- Primary completion
- Dec 30, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT04585477 · updated Jul 7, 2026